Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2019104269 - MÉTHODES D'ACTIVATION, DE MODIFICATION ET D'EXPANSION DE LYMPHOCYTES T GAMMA DELTA POUR LE TRAITEMENT DU CANCER ET DE MALIGNITÉS ASSOCIÉES


Avertissement La version image (PDF) disponible dans PATENTSCOPE est la version officielle. Cette version HTML en ligne est fournie pour aider les utilisateurs. Malgré le grand soin apporté à la compilation pour assurer une représentation précise et exacte des données figurant sur le document/les images imprimés, des erreurs et/ou des omissions ne peuvent pas être exclues en raison des processus de transmission et de conversion de données et des limitations inhérentes aux processus de traduction (éventuellement) automatique utilisés. Les liens hypertexte suivis de ce symbole sont associés à des ressources externes qui ne sont pas contrôlées par l'OMPI. L'OMPI décline toute responsabilité concernant les points mentionnés ci-dessus.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/US2018/062442 3000011-003977
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
26 November 2018 27 November 2017
Applicant
IMMATICS US, INC.
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
METHODS FOR ACTIVATING, MODIFYING AND EXPANDING GAMMA DELTA T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES

5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C12N 5/0783 (2010.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C12N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data, BIOSIS, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
EP 3208329 A1 (UNIV SCHOOL ST MARIANNA MEDICINE [JP]; NAT UNIV CORP HOKKAIDO UNIV [JP) 23 August 2017 (2017-08-23)
15-18,27,28
claims 1-6
(2)
X
HELEEN H. VAN ACKER ET AL, "Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells", JOURNAL OF HEMATOLOGY & ONCOLOGY,Vol. 9, No. 1, 29 September 2016 (2016-09-29),
XP055555493
15-18,27,28
Y
page 2 - page 3; figure 3
1-14,29
page 6
(3)
X
MOHANADH NADA ET AL, "Enhancing adoptive cancer immunotherapy with V[gamma]2V[delta]2 T cells through pulse zoledronate stimulation", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK,Vol. 5, No. 1, 21 February 2017 (2017-02-21), page 1-23,
XP021242440
15-18,27,28
Y
page 2 - page 3; figures 5-6
1-14,29
(4)
X
US 2010009447 A1 (OKAMURA HARUKI [JP] ET AL) 14 January 2010 (2010-01-14)
15-18,27,28
cited in the application
paragraph [0038] - paragraph [0044]
(5)
A
GU YANJUN ET AL, "Rapamycin together with TGF-[beta]1, IL-2 and IL-15 induces the generation of functional regulatory [gamma][delta]T cells from human peripheral blood monon", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL,Vol. 402, No. 1, 22 November 2013 (2013-11-22), page 82-87,
XP028820466
1-29
the whole document
(6)
A
CN 103756962 A (SHANGHAI CLAISON BIOTECHNOLOGY CO LTD) 30 April 2014 (2014-04-30)
1-29
claim 1
(7)
A
WO 2016055996 A1 (TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD [IL]) 14 April 2016 (2016-04-14)
1-29
claims 1-3
(8)
A
WO 2016087871 A1 (KING S COLLEGE LONDON [GB]) 09 June 2016 (2016-06-09)
1-29
claims 1-7; figure 2
(9)
A
GARCÍA V E ET AL, "IL-15 enhances the response of human gamma delta T cells to nonpeptide [correction of nonpetide] microbial antigens.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 01 MAY 1998,Vol. 160, No. 9, 01 May 1998 (1998-05-01), page 4322-4329,
XP002788890
1-29
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
EP 3208329 A1
23 August 2017
EP 3208329 A1
JP 2016077185 A
US 2017240859 A1
WO 2016060111 A1
23 August 2017
16 May 2016
24 August 2017
21 April 2016
US 2010009447 A1
14 January 2010
JP 4281071 B1
JP 2010017134 A
US 2010009447 A1
17 June 2009
28 January 2010
14 January 2010
CN 103756962 A
30 April 2014
CN 102994448 A
CN 103756962 A
27 March 2013
30 April 2014
WO 2016055996 A1
14 April 2016
CN 106795493 A
US 2017296584 A1
WO 2016055996 A1
31 May 2017
19 October 2017
14 April 2016
WO 2016087871 A1
09 June 2016
AU 2015356788 A1
CA 2969783 A1
CN 107208061 A
EP 3227435 A1
JP 2017537625 A
KR 20170084337 A
RU 2017121191 A
US 2017342381 A1
WO 2016087871 A1
13 July 2017
09 June 2016
26 September 2017
11 October 2017
21 December 2017
19 July 2017
10 January 2019
30 November 2017
09 June 2016
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
18 February 2019
Date of mailing of the international search report:
06 March 2019
Authorized officer:
Paresce, Donata
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E